資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://ir.cmu.edu.tw/ir/handle/310903500/29696
|
| 題名: | Improvement of esophageal and gastric motility after 2-week treatment of oral erythromycin in patients with non-insulin-dependent diabetes mellitus |
| 作者: | Chang, CT;Shiau, YC;Lin, CC;Li, TC;Lee, CC;Kao, CH |
| 貢獻者: | 附設醫院核子醫學部;China Med Coll Hosp, Dept Nucl Med, Taichung 404, Taiwan;China Med Coll Hosp, Div Endocrinol & Metab, Taichung, Taiwan;Natl Taiwan Univ, Dept Nucl Med, Far Eastern Mem Hosp, Taipei 10764, Taiwan;Natl Taiwan Univ, Inst Biomed Engn, Coll Elect Engn, Taipei 10764, Taiwan;China Med Coll Hosp, Dept Family Med, Taichung, Taiwan;China Med Coll, Inst Chinese Med, Taichung, Taiwan;China Med Coll Hosp, Dept Med Res, Taichung, Taiwan |
| 日期: | 2003 |
| 上傳時間: | 2010-09-24 14:40:40 (UTC+8) |
| 出版者: | ELSEVIER SCIENCE INC |
| 摘要: | Background. Distant metastasis rather than locoregional recurrence is the major site of failure after adequate radiotherapy in nasopharyngeal carcinoma (NPC). The aim of this study is to evaluate the toxicity and survival of outpatient weekly 24-hour infusion adjuvant chemotherapy for NPC patients with high-risk of distant failure. Methods. Our definition of high-risk NPC included patients with (1) 1992 AJCC staging system of N3, T4N2, or N2 with one of nodal size > 4 cm; (2) supraclavicular node metastasis; and (3) residual disease after radiotherapy or neck relapse. From August 1994 to August 1997, 41 NPC patients matching the preceding criteria agreed to receive weekly PFL (cisplatin 25 mg/m(2), 5-fluorouracil 1250 mg/m(2), and leucovorin 120 mg/m(2)) adjuvant chemotherapy for a total of 18 weeks. Clinical data of another 88 patients with similar disease status who did not receive adjuvant chemotherapy during the same period were collected and analyzed for comparison. Survival analysis was investigated by the Kaplan-Meier method and the Cox proportional hazards model. Results. A total of 700 weekly chemotherapy doses was delivered to 41 patients. The ratio of actual/planned dose delivery was 94.9%. Grade 3-4 toxicity of adjuvant chemotherapy included leucopenia (7.3%), anemia (2.4%), thrombocytopenia (2.4%), and nausea/vomiting (2.4%). After a median follow-up of 70 months, 26.8% (11 of 41) and 47.7% (42 of 88) of patients in PFL and no adjuvant chemotherapy groups had distant metastasis (p =.0247). The 5-year metastasis-free survival rates were 71.9% for the PFL group compared with 48.4% for no adjuvant chemotherapy patients (p =.0187). The 5-year overall survival rates were 53.7% (PFL group) and 38.3% (no adjuvant chemotherapy group), respectively (p =.0666). Multivariate Cox analysis showed PFL adjuvant chemotherapy was the independent factor that predicted metastasis-free survival after adjustment for other variables. Conclusions. Outpatient weekly 24-hour continuous infusion PFL adjuvant chemotherapy is a well-tolerated regimen with promising results in high-risk NPC patients and merits investigation in phase III studies. (C) 2003 Wiley Periodicals, Inc. |
| 關聯: | JOURNAL OF DIABETES AND ITS COMPLICATIONS 17(3):141-144 |
| 顯示於類別: | [台中附設醫院] 期刊論文
|
在CMUR中所有的資料項目都受到原著作權保護.
|
